These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. An Unusual Case of Synchronous Metastatic Melanomas With Differing Response to Pembrolizumab. Doolan BJ; McLean C; Mar V; Moore M J Oncol Pract; 2019 Mar; 15(3):159-160. PubMed ID: 30861362 [No Abstract] [Full Text] [Related]
6. In brief: Avelumab (Bavencio) for metastatic merkel cell carcinoma. Med Lett Drugs Ther; 2017 Jul; 59(1521):e120. PubMed ID: 28699934 [No Abstract] [Full Text] [Related]
7. Pembrolizumab as first line treatment of Merkel cell carcinoma patients - a case series of patients with various co-morbidities. Bystrup Boyles T; Schødt M; Hendel HW; Krarup-Hansen A; Junker N Acta Oncol; 2020 Jul; 59(7):793-796. PubMed ID: 32285728 [No Abstract] [Full Text] [Related]
9. Antitumor and Anti-Hepatitis C Viral Response After Administration of the Anti-Programmed Death 1 Antibody Pembrolizumab. Jang S; Venna S J Oncol Pract; 2017 Jul; 13(7):462-464. PubMed ID: 28562196 [No Abstract] [Full Text] [Related]
10. Persistence of superficial basal cell carcinoma during pembrolizumab treatment for metastatic melanoma. Russo I; Filoni A; Alaibac M Eur J Dermatol; 2021 Feb; 31(1):99-100. PubMed ID: 33586650 [No Abstract] [Full Text] [Related]
11. [Treating metastatic melanoma: Risk management]. Lebbe C; Robert C Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593 [No Abstract] [Full Text] [Related]
12. A case of intraepidermal Merkel cell carcinoma within squamous cell carcinoma in-situ: Merkel cell carcinoma in-situ? Al-Ahmadie HA; Mutasim DF; Mutema GK Am J Dermatopathol; 2004 Jun; 26(3):230-3. PubMed ID: 15166513 [TBL] [Abstract][Full Text] [Related]
13. A rapid response to pembrolizumab in a patient with metastatic melanoma. Bayo Calero J; Aviñó Tarazona V Immunotherapy; 2017 Mar; 9(3):225-228. PubMed ID: 28231724 [TBL] [Abstract][Full Text] [Related]
15. Vitiligo-like lesions located over In-transit metastases of malignant melanoma as a clinical marker of complete response to pembrolizumab. Gracia-Cazaña T; Padgett E; Hernández-García A; Sánchez-Salas MP Dermatol Online J; 2019 Dec; 25(12):. PubMed ID: 32045170 [TBL] [Abstract][Full Text] [Related]
16. Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial. Lambert J; Marrel A; D'Angelo SP; Burgess MA; Chmielowski B; Fazio N; Gambichler T; Grob JJ; Lebbé C; Robert C; Russell J; Güzel G; Bharmal M Patient; 2020 Aug; 13(4):457-467. PubMed ID: 32472503 [TBL] [Abstract][Full Text] [Related]
17. Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions. Nishino M; Giobbie-Hurder A; Manos MP; Bailey N; Buchbinder EI; Ott PA; Ramaiya NH; Hodi FS Clin Cancer Res; 2017 Aug; 23(16):4671-4679. PubMed ID: 28592629 [No Abstract] [Full Text] [Related]
18. Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma Treated With Pembrolizumab. Simetić L; Blažičević K; Međugorac K; Golčić M; Herceg D Anticancer Res; 2020 Apr; 40(4):2157-2163. PubMed ID: 32234909 [TBL] [Abstract][Full Text] [Related]
19. Ipilimumab has efficacy in metastatic Merkel cell carcinoma: a case series of five patients. Winkler JK; Dimitrakopoulou-Strauss A; Sachpekidis C; Enk A; Hassel JC J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):e389-e391. PubMed ID: 28256019 [No Abstract] [Full Text] [Related]
20. Complete Response of Advanced Melanoma Treated With Talimogene Laherparepvec and Subsequent Sweet's-like Infiltrate. Parekh V; Gangadhar T; Kreider KL; Elenitsas R; Chu EY JAMA Dermatol; 2017 Jul; 153(7):719-721. PubMed ID: 28445579 [No Abstract] [Full Text] [Related] [Next] [New Search]